For the primary objective of safety, the analysis set will include: (1) patients who experience an unacceptable toxicity attributable to LITT or SCRT treatment during the 4 weeks after initiation of LITT treatment, and (2) patients who complete LITT and SCRT treatment and are observed for 4 weeks after initiation of LITT treatment. Other safety analyses will include all patients who receive LITT treatment.